Ardelyx Inc (ARDX)

$6.61 -0.07 (-1.05%)
Market Cap 1.59B
Revenue (ttm) 333.62M
Net Income (ttm) -39.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11.73%
Debt to Equity Ratio 1.44
Volume 2,350,200
Avg Vol 4,036,354
Day's Range N/A - N/A
Shares Out 240.98M
Stochastic %K 67%
Beta 0.74
Analysts Strong Sell
Price Target $11.36

Company Profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in Ju...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 745 1700
Address:
400 Fifth Avenue, Suite 210, Waltham, United States
Cameohitch
Cameohitch Sep. 14 at 9:52 AM
$ARDX Pharmacists adding to the pressure on cms with another press release last week: "Starting January 1, 2025, the ESRD bundle payment began covering oral phosphate-binding agents for patients receiving dialysis services. ASCP, along with other organizations representing kidney patients and older adults, opposed this change in our comments to CMS’ draft rule. In a letter dated August 23, 2023, we wrote, “including PLTs in the ESRD PPS not only negatively impacts the health of seniors on dialysis, but it also increases costs for treatment.” Sadly, our warnings were unheeded, and access has been disrupted." https://www.ascp.com/news/709802/ASCP-Comments-on-CMS-Rules-related-to-Dialysis-Services-and-Home-Health-Access-.htm
0 · Reply
Lenni_D
Lenni_D Sep. 14 at 6:50 AM
$ARDX https://investorshangout.com/kidney-care-access-protection-act-a-major-step-forward-391118-/
1 · Reply
Bio_Invest101
Bio_Invest101 Sep. 14 at 1:42 AM
$ARDX https://www.fiercepharma.com/pharma/us-appeals-court-knocks-back-novartis-medicare-price-negotiations-challenge-one-week-after
1 · Reply
Bio_Invest101
Bio_Invest101 Sep. 13 at 6:38 PM
$ARDX Guess no EU entry for now is a good idea. But how much back bone the Congress has against the king’s wishes ? Is 3 yrs instead of 2-yr protected sales Good enough to enter TDAPA in next Jan? Never a good idea to leave 60% of market shares out anywhere. Why not get in first and keep the fights through congress b4 the end of 2029? Please stop pumping Raab to spend the limited cash on a risky ph2-3 trial biotch BO or partnership deal. The old FDA as we all know is not here any more since the new FDA is getting rid of Adcom. Btw X was rescued by Adcom 3 yrs ago in case you forgot. https://kffhealthnews.org/news/article/fda-advisory-committee-meetings-response-letters-makary-transparency-drugs/ https://www.rnz.co.nz/news/world/572968/trump-s-next-plan-to-lower-us-drug-prices-raise-them-in-other-countries
0 · Reply
opportoni
opportoni Sep. 13 at 1:26 PM
$ARDX Hey law bubble, @Elvis50 @watsonturtle @mikerick39, is there any way to find out the exact time the hearing will take place on the 25th or does it depend on how long the previous case (Red Rock v. NLRB) on that day takes?
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 13 at 6:19 AM
Enter: $ARDX OCT 17 2025 $7 CALLS Buy in Price: $0.28 - $0.30 Take Profit: $0.32 Stop Bleeding: $0.25 ROI Potential: 16% Exit Within: 38 Minutes https://moneygroup.us/alerts
0 · Reply
Lenni_D
Lenni_D Sep. 12 at 10:03 PM
$ARDX https://x.com/kcp_tweets/status/1966604026994143668?s=46&t=gMVvVdMhHYj57EjeLvU1yg
0 · Reply
Lenni_D
Lenni_D Sep. 12 at 10:02 PM
$ARDX http://bit.ly/4nsbPNs
0 · Reply
Howardm34
Howardm34 Sep. 12 at 8:11 PM
$ARDX While today and last the last 2 fridays have all been down days, this week marks the 7th straight week we have been GREEN!! Here are the numbers, + .09, .26, . 22, .16, .77, .89 and .04. We were down 8 weeks ago by -.14. It’s interesting that we seem of late to be weaker on Friday’s and it just might be a coincidence that the script numbers have been weaker of late. If the script numbers get back on track in a solid way next week we could see $7 Have a great weekend and Monday can’t come soon enough.
0 · Reply
Krambo88
Krambo88 Sep. 12 at 8:09 PM
$ARDX Double digits seem like a pipe dream!
0 · Reply
Latest News on ARDX
Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 10:11 AM EDT - 6 days ago

Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Ardelyx, Inc. (ARDX) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 4:42 PM EDT - 10 days ago

Ardelyx, Inc. (ARDX) Presents At Citi's Biopharma Back To School Conference Transcript

Ardelyx to Participate in Upcoming Investor Conferences

Aug 25, 2025, 8:00 AM EDT - 20 days ago

Ardelyx to Participate in Upcoming Investor Conferences

Ardelyx: Improved Outlook For Ibsrela And Xphozah

Aug 15, 2025, 6:17 AM EDT - 4 weeks ago

Ardelyx: Improved Outlook For Ibsrela And Xphozah

Ardelyx, Inc. (ARDX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 8:11 PM EDT - 5 weeks ago

Ardelyx, Inc. (ARDX) Q2 2025 Earnings Call Transcript

Ardelyx Announces Changes to the Executive Leadership Team

Aug 4, 2025, 4:08 PM EDT - 5 weeks ago

Ardelyx Announces Changes to the Executive Leadership Team

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 4:01 PM EDT - 5 weeks ago

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Jul 21, 2025, 8:00 AM EDT - 7 weeks ago

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

Jun 2, 2025, 4:05 PM EDT - 3 months ago

Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

May 21, 2025, 8:00 AM EDT - 4 months ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

May 6, 2025, 8:01 AM EDT - 4 months ago

Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty

May 2, 2025, 10:07 AM EDT - 4 months ago

Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty

Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript

May 1, 2025, 10:06 PM EDT - 4 months ago

Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 4:01 PM EDT - 4 months ago

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Apr 29, 2025, 8:00 AM EDT - 4 months ago

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

Apr 24, 2025, 8:01 AM EDT - 5 months ago

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

Apr 17, 2025, 8:00 AM EDT - 5 months ago

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings

Apr 10, 2025, 4:02 PM EDT - 5 months ago

Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings

Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings

Mar 31, 2025, 4:03 PM EDT - 5 months ago

Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings

Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

Mar 13, 2025, 8:02 AM EDT - 6 months ago

Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

Undercovered Dozen: Ardelyx, Aviva, Nutrien, Heartland Express +

Mar 1, 2025, 8:30 AM EST - 7 months ago

Undercovered Dozen: Ardelyx, Aviva, Nutrien, Heartland Express +

HTLD NTR

Tenapanor Approved in China for Hyperphosphatemia

Feb 26, 2025, 7:00 AM EST - 7 months ago

Tenapanor Approved in China for Hyperphosphatemia

Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)

Feb 24, 2025, 2:28 PM EST - 7 months ago

Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)

3 Biotech/Healthcare Names Under $10 I Am Buying Now

Feb 21, 2025, 4:21 PM EST - 7 months ago

3 Biotech/Healthcare Names Under $10 I Am Buying Now

GERN MRNA PSNL TEM

Ardelyx, Inc. (ARDX) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 2:32 PM EST - 7 months ago

Ardelyx, Inc. (ARDX) Q4 2024 Earnings Call Transcript

Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 20, 2025, 7:30 AM EST - 7 months ago

Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference

Feb 19, 2025, 8:01 AM EST - 7 months ago

Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference

Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025

Jan 30, 2025, 4:30 PM EST - 8 months ago

Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025

Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities

Jan 13, 2025, 8:03 AM EST - 8 months ago

Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities

Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:00 AM EST - 8 months ago

Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It

Nov 24, 2024, 6:36 AM EST - 10 months ago

Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It

Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 8:00 AM EST - 10 months ago

Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference

Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability

Nov 14, 2024, 9:34 AM EST - 10 months ago

Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability

Ardelyx Responds to District Court Decision Granting Motion to Dismiss

Nov 8, 2024, 12:31 PM EST - 11 months ago

Ardelyx Responds to District Court Decision Granting Motion to Dismiss

Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference

Nov 5, 2024, 8:00 AM EST - 11 months ago

Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference

Ardelyx, Inc. (ARDX) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 11:20 PM EDT - 11 months ago

Ardelyx, Inc. (ARDX) Q3 2024 Earnings Call Transcript

Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 31, 2024, 4:02 PM EDT - 11 months ago

Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update

Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology's (ACG) Annual Meeting

Oct 28, 2024, 4:05 PM EDT - 11 months ago

Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology's (ACG) Annual Meeting

Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community

Oct 22, 2024, 4:05 PM EDT - 11 months ago

Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community

Cameohitch
Cameohitch Sep. 14 at 9:52 AM
$ARDX Pharmacists adding to the pressure on cms with another press release last week: "Starting January 1, 2025, the ESRD bundle payment began covering oral phosphate-binding agents for patients receiving dialysis services. ASCP, along with other organizations representing kidney patients and older adults, opposed this change in our comments to CMS’ draft rule. In a letter dated August 23, 2023, we wrote, “including PLTs in the ESRD PPS not only negatively impacts the health of seniors on dialysis, but it also increases costs for treatment.” Sadly, our warnings were unheeded, and access has been disrupted." https://www.ascp.com/news/709802/ASCP-Comments-on-CMS-Rules-related-to-Dialysis-Services-and-Home-Health-Access-.htm
0 · Reply
Lenni_D
Lenni_D Sep. 14 at 6:50 AM
$ARDX https://investorshangout.com/kidney-care-access-protection-act-a-major-step-forward-391118-/
1 · Reply
Bio_Invest101
Bio_Invest101 Sep. 14 at 1:42 AM
$ARDX https://www.fiercepharma.com/pharma/us-appeals-court-knocks-back-novartis-medicare-price-negotiations-challenge-one-week-after
1 · Reply
Bio_Invest101
Bio_Invest101 Sep. 13 at 6:38 PM
$ARDX Guess no EU entry for now is a good idea. But how much back bone the Congress has against the king’s wishes ? Is 3 yrs instead of 2-yr protected sales Good enough to enter TDAPA in next Jan? Never a good idea to leave 60% of market shares out anywhere. Why not get in first and keep the fights through congress b4 the end of 2029? Please stop pumping Raab to spend the limited cash on a risky ph2-3 trial biotch BO or partnership deal. The old FDA as we all know is not here any more since the new FDA is getting rid of Adcom. Btw X was rescued by Adcom 3 yrs ago in case you forgot. https://kffhealthnews.org/news/article/fda-advisory-committee-meetings-response-letters-makary-transparency-drugs/ https://www.rnz.co.nz/news/world/572968/trump-s-next-plan-to-lower-us-drug-prices-raise-them-in-other-countries
0 · Reply
opportoni
opportoni Sep. 13 at 1:26 PM
$ARDX Hey law bubble, @Elvis50 @watsonturtle @mikerick39, is there any way to find out the exact time the hearing will take place on the 25th or does it depend on how long the previous case (Red Rock v. NLRB) on that day takes?
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 13 at 6:19 AM
Enter: $ARDX OCT 17 2025 $7 CALLS Buy in Price: $0.28 - $0.30 Take Profit: $0.32 Stop Bleeding: $0.25 ROI Potential: 16% Exit Within: 38 Minutes https://moneygroup.us/alerts
0 · Reply
Lenni_D
Lenni_D Sep. 12 at 10:03 PM
$ARDX https://x.com/kcp_tweets/status/1966604026994143668?s=46&t=gMVvVdMhHYj57EjeLvU1yg
0 · Reply
Lenni_D
Lenni_D Sep. 12 at 10:02 PM
$ARDX http://bit.ly/4nsbPNs
0 · Reply
Howardm34
Howardm34 Sep. 12 at 8:11 PM
$ARDX While today and last the last 2 fridays have all been down days, this week marks the 7th straight week we have been GREEN!! Here are the numbers, + .09, .26, . 22, .16, .77, .89 and .04. We were down 8 weeks ago by -.14. It’s interesting that we seem of late to be weaker on Friday’s and it just might be a coincidence that the script numbers have been weaker of late. If the script numbers get back on track in a solid way next week we could see $7 Have a great weekend and Monday can’t come soon enough.
0 · Reply
Krambo88
Krambo88 Sep. 12 at 8:09 PM
$ARDX Double digits seem like a pipe dream!
0 · Reply
FerreroRocher
FerreroRocher Sep. 12 at 8:00 PM
$ARDX Is it Monday yet?
0 · Reply
GladysFoster
GladysFoster Sep. 12 at 7:09 PM
$ARDX if it stays above 6.60 it'll be a good start to the weekend..
2 · Reply
opportoni
opportoni Sep. 12 at 6:34 PM
$ARDX Aujourd'hui la même chose.
1 · Reply
rekcals
rekcals Sep. 12 at 5:53 PM
$AKBA remember when $AKBA had a higher stock price and market cap than $ARDX for a day.
1 · Reply
ChandlerBing74
ChandlerBing74 Sep. 12 at 5:51 PM
$ARDX MM looking for shares
2 · Reply
jaw02
jaw02 Sep. 12 at 2:44 PM
$ARDX Kidney Care Access Protection Act is officially S.2730. It has been referred to senate finance committee. https://www.congress.gov/bill/119th-congress/senate-bill/2730
2 · Reply
NoamStocksy
NoamStocksy Sep. 12 at 2:11 PM
$ARDX Honestly, what a legend he is. Thanks again!!
2 · Reply
Lenni_D
Lenni_D Sep. 12 at 1:46 PM
$ARDX Wouldn't KCAPA in the present form keep X in the bundle, change TDAPA from 2 to 3 years and improve the post TDAPA bundle payment for dialysis centers? I doubt that Ardelyx would apply? The size of the bundle payment means nothing imo. After the TDAPA period every X script would be taken out of the dialysis centers profits.
3 · Reply
shoagh12
shoagh12 Sep. 12 at 1:46 PM
$ARDX
0 · Reply
M_OF_E
M_OF_E Sep. 12 at 11:55 AM
$ARDX Weeek includes Labor day. Looks as if it had a big negative effect. Ibsrela TRx lowest since May. Since 4 weeks before was a reasonably strong number, the 4 week sum(Total Patients) took a decent hit. First major drop for that in a long time and back to around the level for the week of 7/11. NRx was the biggest drop, with the paper work for Prior Authorization, Holidays can do that. RRx while some weakness held up pretty well. So hopefully that ends the seasonality period and it starts showing the strength it did in July. In any case I think based on scripts it is still above analyst estimates for revenue. Xphozah while down on a 4 week basis, not by a lot but well below the strong number 2 weeks ago. Still in the channel.
15 · Reply
Microscope
Microscope Sep. 12 at 11:03 AM
$ARDX https://chatgpt.com/s/t_68c3fdd38d388191bf42c383dfef0a43
1 · Reply
opportoni
opportoni Sep. 12 at 8:13 AM
$ARDX So basically we are in a better position now than in 2024. We are back to having 2 silver bullets: The legal case in front of the appeals court and a legislative initiative in congress. Either one could bring tremendous upside to Xphozah by improving the reimbursement situation. The situation is better because we now already have proof that there is also a significant business for Xphozah if both fail.
1 · Reply